Loading
A phase 1/2 trial of CKD-703 in non-small-cell lung cancer, run by Chong Kun Dang Pharmaceutical, now recruiting.
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07439094 by Chong Kun Dang Pharmaceutical, with 140 participants planned, started 2026-04-16 and due to reach its primary completion in 2029-12. Interventions recorded: CKD-703.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/